Navepegritid

Achondroplasia is caused by constitutive activation of fibroblast growth factor receptor 3 (FGFR3), which slows the linear growth of bones at the growth plates. Navepegritide is a prodrug: via the TransCon carrier technology (the same basic principle as the parathyroid hormone prodrug palopegteriparatide), the active C-type natriuretic peptide (CNP) is temporarily bound to an inert carrier and is slowly and steadily released after injection, so that a sustained CNP exposure is maintained across the weekly interval. The released CNP binds to natriuretic peptide receptor B (NPR-B) on the cartilage cells (chondrocytes) of the growth plates and there increases cGMP and protein kinase G signaling, which counteracts the FGFR3 signaling that is overactive in achondroplasia and inhibits the downstream MAPK signaling pathway (according to the FDA prescribing information). This promotes the division and maturation of chondrocytes and partly compensates for the impaired linear growth. Conceptually decisive: the active substance does NOT act on the growth hormone/IGF-1 axis, but rather acts in a paracrine manner directly on the cartilage - and only where the epiphyses are still open.

The diagnosis of achondroplasia must be confirmed, and patients must have open epiphyses. The US approval was granted on an accelerated basis on the surrogate endpoint "annualized growth velocity"; according to the FDA label, continued approval depends on confirmation of clinical benefit in confirmatory studies. This profile states no doses, concentrations, or preparation/injection steps.

Navepegritide emerged from Ascendis Pharma's TransCon platform, which converts short-acting active substances into a depot form through reversible binding to an inert carrier. Development included the Phase 2 dose-finding study ACcomplisH (NCT04085523, start 24 June 2020, completed) in 57 children with achondroplasia aged 2 to 10 years; the primary endpoint was annualized growth velocity after 52 weeks. This was followed by the pivotal study ApproaCH (NCT05598320, start 2023) - a multicenter, double-blind, randomized, placebo-controlled study in 84 children (2 to 11 years) at 10 centers in seven countries, listed in the registry as Phase 2/3 and published as a Phase 2b study (JAMA Pediatrics 2026;180(1):18-25, online ahead of print November 2025, print edition January 2026; first author R. Savarirayan; study results posted to the registry on 14 July 2026). The FDA granted accelerated approval for Yuviwel on 27 February 2026; according to an Ascendis statement of 6 April 2026, the product has been commercially available in the USA since then and carries FDA orphan drug exclusivity. In Europe, the CHMP issued a positive marketing authorization recommendation on 15 October 2026; the decision by the European Commission was still pending as of 24 October 2026 (expected by the manufacturer for the fourth quarter of 2026, with a planned first EU launch in Germany in the first quarter of 2027 - manufacturer's information).